A Phase 3 interventional study of exemestane (Aromasin) and tamoxifen + exemestane in Breast Neoplasms, sponsored by Pfizer. Completed at 179 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.
Among the 103 studies testing exemestane in Breast Neoplasms, this one has the largest enrollment of the 101 interventional ones that give a count, is one of 8 that started in 2001, is one of 34 in phase 3, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Andrea DeCensi · Sites in Italy
Women only
Peking University People's Hospital · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, exemestane is the treatment under test here. Read study by study →
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 52 · Phase 3 36 · Phase 4 7
First in 1996; this study’s year is marked. 8 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9,779 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 123 across the 101 interventional studies. Of the 60 that completed or were terminated, 27 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 103 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one has the largest enrollment of the 121 interventional ones that give a count, is one of 3 that started in 2001, is one of 25 in phase 3, and was the 3rd registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
4 of the studies testing exemestane in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT06364267Andrea DeCensiLow Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. | 2027-01-31 |
| NCT07499999Dana-Farber Cancer InstituteRandomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer | 2027-08-31 |
| NCT07299890Anhui Provincial Cancer HospitalAn Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 103 studies testing exemestane in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer.
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: exemestane (Aromasin)
Drug: tamoxifen + exemestane
exemestane, orally, 25 mg, for 5 years
Also known as: aromasin
Drug pages: Tamoxifen · Exemestane
tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.
Time frame: Baseline (Month 0) up to 2.75 years
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.
Time frame: Baseline (Month 0) up to 5 years
Number of Events for Overall Survival (OS)
Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.
Time frame: Baseline (Month 0) up to 5 years
Time to New Primary Breast Cancers
New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).
Time frame: Baseline (Month 0) up to 5 years
Number of Events for Time to Relapse
Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.
Time frame: Baseline (Month 0) up to 5 years
Number of Participants With New Primary Non-breast Cancers
Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.
Time frame: Baseline (Month 0) up to 5 years
| Milestone | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Started | 4904 | 4875 |
| Completed | 4898 | 4868 |
| Not completed | 6 | 7 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Milestone | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Started | 4898 | 4868 |
| Treated | 4852 | 4814 |
| Completed | 2333 | 1380 |
| Not completed | 2565 | 3488 |
| Withdrew: Ongoing | 1081 | 736 |
| Withdrew: Disease- free survival (dfs) event | 507 | 447 |
| Withdrew: Adverse event | 501 | 782 |
| Withdrew: Other | 277 | 288 |
| Withdrew: Treatment refusal | 113 | 208 |
| Withdrew: Randomized but not treated | 46 | 54 |
| Withdrew: Protocol violation | 23 | 91 |
| Withdrew: Intercurrent illness | 17 | 29 |
| Withdrew: Too early switch | 0 | 103 |
| Withdrew: No/too late switch/refusal to switch | 0 | 750 |
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.
| Events (disease relapse or death) | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years | 352 | 388 |
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.
| Events (disease relapse or death) | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years | 712 | 714 |
Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.
| Events (death) | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Number of Events for Overall Survival (OS) | 485 | 476 |
New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).
No measurements were reported for this outcome.
Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.
| Events (disease relapse) | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Number of Events for Time to Relapse | 499 | 521 |
Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.
| Participants | Exemestane | Tamoxifen Followed by Exemestane |
|---|---|---|
| Colorectal cancer | 43 | 32 |
| Lung cancer | 24 | 17 |
| Endometrial cancer | 7 | 17 |
| DCIS | 3 | 4 |
| Other primary cancer types | 110 | 106 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tamoxifen Followed by Exemestane | — | 784/4,814 (16.3%) | 3,551/4,814 (73.8%) |
| Exemestane | — | 831/4,852 (17.1%) | 3,567/4,852 (73.5%) |
| Event | Tamoxifen Followed by Exemestane | Exemestane |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 14/4814 | 34/4852 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/4814 | 28/4852 |
| FractureInjury, poisoning and procedural complications | 15/4814 | 27/4852 |
| PneumoniaInfections and infestations | 26/4814 | 25/4852 |
| Cerebrovascular accidentNervous system disorders | 20/4814 | 26/4852 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 22/4814 | 24/4852 |
| Myocardial infarctionCardiac disorders | 18/4814 | 18/4852 |
| Atrial fibrillationCardiac disorders | 15/4814 | 18/4852 |
| Endometrial hyperplasiaReproductive system and breast disorders | 17/4814 | 0/4852 |
| Chest painGeneral disorders | 15/4814 | 16/4852 |
| Event | Tamoxifen Followed by Exemestane | Exemestane |
|---|---|---|
| Hot flushVascular disorders | 1690/4814 | 1517/4852 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1002/4814 | 1157/4852 |
| FatigueGeneral disorders | 800/4814 | 796/4852 |
| InsomniaPsychiatric disorders | 452/4814 | 549/4852 |
| PainGeneral disorders | 492/4814 | 541/4852 |
| NauseaGastrointestinal disorders | 482/4814 | 419/4852 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 219/4814 | 428/4852 |
| DepressionPsychiatric disorders | 417/4814 | 404/4852 |
| Weight increasedInvestigations | 415/4814 | 339/4852 |
| HeadacheNervous system disorders | 372/4814 | 369/4852 |
| Age, Continuous(Years) | Exemestane | Tamoxifen Followed by Exemestane | Total |
|---|---|---|---|
| Mean | 65 ± 9 | 64 ± 9 | 64 ± 9 |
| Age, Customized(Participants) | Exemestane | Tamoxifen Followed by Exemestane | Total |
|---|---|---|---|
| Less than 50 years | 171 | 160 | 331 |
| 50 to 59 years | 1510 | 1507 | 3017 |
| 60 to 69 years | 1835 | 1896 | 3731 |
| Greater than and equal to 70 years | 1382 | 1305 | 2687 |
| Sex: Female, Male(Participants) | Exemestane | Tamoxifen Followed by Exemestane | Total |
|---|---|---|---|
| Female | 4898 | 4868 | 9766 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 179 sites. Choose a country and city above to see the rest.
The record gives a start of Aug 2001, a primary completion of Oct 2008 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Exemestane · Tamoxifen